Dr. Stanley Hirsch, Group CEO
Prior to joining FuturaGene, Dr. Hirsch was responsible for business development for a privately held group of healthcare companies, where he oversaw the structuring and managing of joint ventures, startup companies, technology licensing and new product acquisitions. Previously, he has also served as general manager of two diagnostics development companies. Dr. Hirsch has been involved in the development of automated systems for plant tissue culture and he is a co-inventor of patents in plant biotechnology and micropropagation systems. Dr. Hirsch received his D. Phil. from Oxford University in cell biology and immunology.

Dr. Ziv Shani, Senior Vice President R&D
Prior to his appointment as FuturaGene’s Senior Vice President, Dr. Shani was VP R&D at CBD Technologies Ltd. and held that position since 2006. He joined CBD in 1999 and was responsible for the set up and development of the agricultural biotech program at CBD, which subsequently developed into the main line of activity of CBD and later of FuturaGene. He received his B.Sc., M.Sc. and Ph.D. degrees from the Hebrew University of Jerusalem. Dr. Shani is a leading contributor to research and development in the field of agricultural biotechnology.

Mr. John Corre, FCA- Senior Vice President Finance & CFO
Mr. Corre joined FuturaGene in 2009. He is a UK qualified Chartered Accountant, who was for many years a senior partner at Auerbach Hope (now AH Montpelier), a leading firm of Chartered Accounts based in the West End of London. Mr. Corre has served on the Board of Directors of many companies, both private and public, and has served as the Chairman of the Board of a number of publicly listed companies. Mr. Corre's responsibilities at FuturaGene include overseeing the financial affairs of the FuturaGene subsidiaries in Israel, USA, Brazil & China.

Mr. Daniel Siegel, Vice President Technology & IP Assessment
Mr. Siegel, a registered US Patent Agent, has over 15 years of experience in the agbio/medical device/biotech industries in product development, intellectual property assessment & due diligence, business intelligence and international business development. In addition to private consulting for a large number of start-ups and mature companies, Mr. Siegel has served as VP Project Assessment at Meytav Technological Incubator, VP BD & IP Strategy at CollPlant Ltd., and VP BD & Licensing at CBD Technologies, Ltd., establishing and executing several key international strategic relationships, licensing and M&A deals.

Mr. Eduardo Jose de Mello, Vice President Operations Brazil & Global Tree Improvement
Mr. Mello has over 24 years of experience in the genetic improvement of eucalyptus. At Suzano, Eduardo worked on the development of several varieties of eucalyptus, which are currently planted over more than 300,000 hectares in Brazil. During his tenure at Suzano, Eduardo rose to hold the position of Executive Manager of Forest R&D. Early in 2011, Eduardo moved from Suzano to take up the position of VP of Operations Brazil and Global Tree Improvement at FuturaGene. Eduardo graduated in Forestry from the University of Sao Paulo and is an expert in Genetic Improvement, Project Management and holds an MBA from Fundação Getúlio Vargas, Brazil.

Mr. James (Hui) Zhang, Vice President China
Mr. Zhang worked in the Department of Agriculture of Gansu Province, China for more than 16 years and held the position of deputy director in the International Cooperation Division. In this position, he was the principal official for developing international and bilateral cooperation relationships to enhance technology and personnel exchanges in the department. He served as Vice President of eSolux Software (Shanghai) Co., Ltd. for three years before he joined FuturaGene. He established FuturaGene China business in 2005. Mr. Zhang received his B.Sc. from China Agricultural University (CAU) and visiting scholar for two year at the University of California, Davis.

Dr. Michael May, Vice President Public Affairs
Michael joined FuturaGene in 2012, bringing a career-long experience in international cooperation in the biotech sector in different cultural and professional settings around the world. Michael read Biological Sciences at the University of Edinburgh before completing his PhD at the University of Warwick. He subsequently gained more than a decade’s postdoctoral experience in genetics and molecular biology at the University of Oxford and the University of Gent, Belgium, publishing more than 40 scientific papers. Prior to joining FuturaGene, Michael held a number of positions in companies, academia and as an entrepreneur which helped shape his interest in policy and its role in driving the creation, uptake and diffusion of advanced technologies as solutions for global challenges.

back to top